Fifth Annual BioE2E Alternative Funding Fair

Saturday, October 7, 2006
8:30 a.m. to 3:00 p.m.
Byers Auditorium, Genentech Hall
UC San Francisco Mission Bay Campus

Cosponsored by
BioE2E, QB3, UCSF Office of Technology Management,
and Wilson Sonsini Goodrich Rosati

Symposium Agenda

Click Here to Register

For More Information:
Contact Douglas Crawford
QB3 Associate Executive Director
douglas.crawford@ucsf.edu
415-514-4408

In today's tough environment for VC funding, entrepreneurs need to access alternative funding sources – including government agencies and foundations. US and state government agencies and philanthropic foundations provide funds and non-cash resources to small biotechnology companies with innovative technologies in the form of grants, contracts, screening services and other development assistance. Government grants and contracts can provide non-dilutive funding, validation from peers, feedback from experts and prestige, while services help you to advance programs while conserving cash.

Invited speakers and topics include:

Defense Sciences Office, DARPA
Michael Callahan MD, Program Manager
The Joint Development Program (JTD) for Cancer Drug Development
Joseph Tomaszewski, PhD, Deputy Director, Division of Cancer Treatment and Diagnosis (DCTD), National Cancer Institute
Industry-University Collaborations
Susanne Huttner, PhD, University of California Associate Vice Provost for Research
Building your Company Without VC Money
Dan Schwartz, MD, Founder, Calhoun Vision, Inc. and Associate Professor and Director of the Retina Division in the Department of Ophthalmology at UCSF
Solicitations, Strategies and Discourse: Keys to Success for Funds
Cori Gorman, PhD MBA, Principal, DNA Bridges
The NIH SBIR/STTR Program, NIAID Programs, and Electronic Submission
Gregory Milman, PhD, Director, Office for Innovation and Special Programs, Division of Extramural Activities, NIAID, NIH
Stem Cell Funding in California - An Update from CIRM
Gilberto Sambrano, PhD, Scientific Review Officer, California Institute for Regenerative medicine (CIRM)
IP Issues for Grant Applications
Laurence J Hyman, JD MSc, Townsend and Townsend and Crew
Panel: Innovative Philanthropic Foundations Fund Emerging Biotech
Panelists include Kate Carr, President & CEO Accelerate Brain Cancer Cure (ABC2), and Robert Pacifici and Tom Base of CHDI, Inc., the not-for-profit drug discovery-development arm of High Q Foundation
Panel: Incubators and Accelerator

In addition to the speakers, representatives from the following organizations and resources will be available for consultation.

SRI/ Pharmastart
QB3 Garage
San Jose Bioscience Center
MMRI
Wilson Sonsini Goodrich Rosati
Grant Writing Services
Angel Investors

Cost

$75 if pre-registered and $150 at the event, cash or check only. The student/post-doc rate for attending this event is $35, if pre-registered. Register online here . Pre-registration closes Tuesday, October 3..